Latest News !
 

Federal Budget 2012: Neutral To Positive For Biotech

Biota Buys Nabi For Its $52m Cash, Nasdaq Listing

MIPS Prof Bill Charman: From Pharmacy College
To Biotech Crucible - Plus  

Why Dr Richard Treagus Is Leaving Acrux

WEHI's Prof Doug Hilton: Evolution & Very Intelligent Design

2011 - The Year In Review

 

April BDI-40 Flat, ASX200 Up 1.4%
Heartware, Sirtex, Cellmid, Psivida Up
Sunshine Heart Down

 

May 1, 2012

The Biotech Daily Top 40 Index (BDI-40) barely changed in April, down 0.07 percent to a market capitalization of $7,556 million, compared to the S&P ASX200 up 1.4 percent.

 

For the year to April 30, the BDI-40 (which does not include the Big Caps of Cochlear, CSL and Resmed) was down 7.8 percent from its all-time high of $8,197 million, compared to the ASX200 falling 8.8 percent for the year and 34.9 percent below its all-time high at October 30, 2007.

 

Since June 30, 2006, the BDI-40 has climbed 112 percent, while the ASX 200 has fallen 13.3 percent.

 

The Big Caps were up 3.2 percent for the month, with CSL up 0.6 percent to $18,861 million, Cochlear up 8.1 percent to $3,737 million and Resmed up 10.1 percent to $5,089 million. The Big Caps were down just 0.5 percent over the 12 months to April 30.

 

Fourteen of the BDI-40 stocks were up, 19 fell and seven were untraded. The BDI-20 was up $49 million, primarily Heartware’s $169 million or 19.0 percent jump on a favorable FDA Panel vote (BD: Apr 26, 2012), while the Second 20 fell $54 million with Phosphagenics $25 million fall the single largest.

 

Cellmid was technically the best up 33.3 percent from a low base to $8 million, followed by last month’s best, Psivida, up a further 25 percent to $50 million; but the 23.6 percent improvement by Sirtex was more significant, up $69 million to $361 million, followed by Genera Biosystems (23.1%), Heartware (19.0%), Neuren (17.2%), Benitec (11.8%) and Phylogica (10.0%).

 

Sunshine Heart led the falls for the second month in a row, down $8 million or 18.6 percent to $35 million, followed by Bioniche down 17.4 percent to $57 million, Avita (15.8%), Biota (14.4%), Bionomics (13.0%), Optiscan (11.1%), Impedimed (10.7%), Antisense (10.5%), Prima (10.5%), Prana (10.4%) and Viralytics (10.3%).

BDI-40 v ASX200 Apr 30, 2011 - Apr 30, 2012

 

 

BDI-40 v S&P ASX200 Jun 30, 2006 - Apr 30, 2012